(Q42628740)

4 November 2017

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia (English)

1 reference

4 November 2017

1 reference

1 reference

3

1 reference

4 November 2017

5

1 reference

4 November 2017

Elisabetta Antonioli

1

1 reference

4 November 2017

Alessandra Carobbio

2

1 reference

4 November 2017

Alessandro Pancrazzi

4

1 reference

4 November 2017

Federica Delaini

6

1 reference

4 November 2017

Vanessa Ponziani

7

1 reference

4 November 2017

Niccolò Bartalucci

8

1 reference

4 November 2017

Lorenzo Tozzi

9

1 reference

4 November 2017

Alberto Bosi

10

1 reference

4 November 2017

Alessandro Rambaldi

11

1 reference

4 November 2017

Tiziano Barbui

12

1 reference

4 November 2017

Alessandro M Vannucchi

13

1 reference

4 November 2017

23 April 2010

1 reference

4 November 2017

1 reference

4 November 2017

95

1 reference

4 November 2017

8

1 reference

4 November 2017

1435-1438

1 reference

JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

4 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913097

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913097

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913097

Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913097

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913097

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913097

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913097

Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913097

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20418246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20418246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2009.021444

1 reference

4 November 2017

1 reference

4 November 2017

PubMed publication ID

20418246

1 reference